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Recent reports from different laboratories have provided conclusive evidence 
that the graft-versus-host  reaction (GVHR) 1 can induce lymphomas (1-4). The 
etiologic  mechanisms,  however,  were  not  well  defined.  Although  most  tu- 
mors induced by this reaction have been found by transplantation studies to be 
of host genotype, several experimenters have observed the induction of tumors 
which were presumed to be of the same genotype as the parental cells utilized for 
induction of the GVHR  (3, 4)  and hence of donor origin. This was considered 
evidence supporting the hypothesis of Tyler (5)  that  excessive immunological 
stimulation of the donor parental cells by the foreign component of the F1 hy- 
brid could result in unrestrained growth of these cells. Hays (6) observed that 
when  mice which had previously received intrathymic injection of Gross leu- 
kemia virus were used as donor mice in the GVHR, the induction of lymphomas 
was facilitated; the virus could also be isolated from the induced tumors.  In a 
separate  experiment,  she  observed  that  cell-free preparations of donor spleen 
cells could induce  lymphomas  (7).  Recently,  by selecting mouse  strains with 
known viral leukemogenic potentialities for such experiments, results have been 
obtained which provide concrete evidence for a viral etiology of GVHR-induced 
tumors. 
Materials and Methods 
MIce.--C57BL/1  (B), SJL/J  (S), A,  (SJL/J X  C57BL/1)F1  ([SB]F1), and  (C57BL/1  X 
A)F1 ([BA]F1) mice used in these experiments  were obtained from the author's colony. The 
B and A strains were obtained in 1967 from the University of Minnesota, Minneapolis, Minn., 
and are descended from the colony of the late Dr. J. J. Bittner. The S mice were obtained from 
Dr.  E.  Murphy, Jackson Laboratory, Bar Harbor, Maine, in  1968. The inbred strains are 
maintained by strict brother-sister mating. 
Viable Spleen Cell  Suspensions.--These  were prepared by a standard technique (4). 
Frozen and Thawed Spleen Cell Suspensions.--After  preparation as a viable cell suspension 
(and a cell count)  the inoculum was frozen at --76°C,  then thawed in a water bath at 38°C. 
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This was carried out a  total of four times. The volume injected was equivalent to that for a 
viable suspension with a similar cell count. 
Liver Suspensions.  -These were prepared in a similar manner to the spleen cell suspensions 
(4). The dose given was equivalent, in milligrams, to that of the viable spleen suspension. 
Preparation o[ Viable Tumor Cell Suspensions.--These were prepared by a standard tech- 
nique (4) so as to ohtain a 33% (w/v) suspension. 0.3-0.6 ml (approximately 0.1 ml/3 g body 
weight) of the suspension was injected intraperitoneally into 25-3S-day old  (weanling) mice. 
Preparation *~t"  Cell-Free Tumor Extract.--A combination of the techniques of Gross (8) and 
Jasmin (9) were used. The tumor was removed rapidly while the mouse was undei ether anes- 
thesia and plunged into lactated Ringer's solution at 0°C.  (All additional manipulations were 
carried out at 0°C.) It was then weighed, cut into small pieces with scissors,  and suspended in 
lactated Ringer's solution (20% w/v).  The tumor fragments were then broken down with a 
Potter-Elvehjem homogenizer (Coming Glass Works, Corning, N.Y.)  with  a  loosely fitting 
stem; thereafter the cell suspension was ground  for 5  min  in  the same homogenizer using 
a tightly fitting stem. The suspension was centrifuged for 15 min at 1400 g; the supernatant was 
removed and recentrifuged at 7000 g for 15 rain. To the supernatant of the second centrifuga- 
tion, polyethylene glycol (Carbowax 6000), was added to a 5% (w/v) concentration. The mLx- 
ture was incubated for 3  hr at 0°C.  The precipitate was resuspended in sufficient lactated 
Ringer's solution to permit ready passage through a No.  30 needle. 0.1 ml of this suspension 
was injected intraperitoneally into newborn (Iess  than 24  hr old)  (BA)F1 and B  mice.  The 
polyethylene glycol technique permitted a four- to sixfold concentration of the cell-free extract. 
Experimental Design and Observations.  The following groups of mice were used: (a) (SB)F1 
mice given five weekly intraperitoneal injections of 6-8 X  106 spleen cells from 4-5-month old 
male S donors. Total cell dosage was 37 X  106 cells in 4 wk; (b)  (SB)F1 mice given frozen and 
thawed  S spleen cells;  (c)  (SB)F1 mice given S liver; (d)  (SB)Fa mice given viable (SB)F1 
spleen cells from 4-5-month old (SB)F1 donors; and  (e) normal (SB)F1 mice. Groups b, c, and d 
were injected according to the dosage schedule for group a. Host (SB)FI mice were 30-44 days 
old; each group consisted of approximately equal numbers of males and females. During the 
first 40 days, the experimental and control groups were observed daily, weighed twice weekly, 
and examined twice weekly for splenic and lymph node enlargement. At 40 days all animals in 
groups a and b were autopsied and tumor transplantation was carried out. Thereafter, observa- 
tion and examination of the remaining groups were carried out weekly. 
After  transplantation of viable tumor ot  cell-free tumor preparation,  the groups of host 
animals (see Results) were examined twice weekly. Tumor growth was confirmed by autopsy 
and histologic studies. Additional transplantation of some of  these tumors was carried out. 
RESULTS 
The  results  are  summarized  in  Table  I.  16  (SB)F~  mice  received  viable  S 
spleen  cells  (group  a).  During  the  4th  wk  after  the  initial  injection  of  cells, 
weight loss as a  result of the GVHR  was noted in 7  of the 16 mice. On the 33rd 
day,  two  mice  died  of  acute  allogeneic  disease,  with  no  evidence  of  tumor  on 
autopsy.  On  day 40,  the remaining  14 mice were  found  to  have  large  spleens; 
autopsy and transplantation studies were carried out. Spleen weight varied from 
0.8  to  2.5  g.  The  mesenteric,  retroperitoneal,  mediastinal,  and cervical  lymph 
nodes were most frequently enlarged. Histologically,  the tumors were reticulum 
cell sarcomas, with numerous mitoses, and with fairlx uniform cytology (Dunn's 
tspe A reticulum cell sarcoma [101). Some areas of lymphosarcoma were present. 
The normal cytology of spleen and lymph nodes was ahnost completely replaced 
by  tumor;  in many  lymph  nodes  there was  evidence of  extension into  the sur- EUGENE  A.  CORNELIUS  1535 
TABLE I 
Lymphoma Induction in (SB)F1 Mice by the GVHR 
Group  Inoculum  Observation period  Tumors* 
days 
a  Viable S spleen cells  40  14/14 
b  Frozen and thawed S spleen cells  40  11/11 
c  S liver  120  0/17 
d  Viable (SB)F1 spleen cells  120  0/15 
e  --  120  0/30:~ 
* No.  mice with  histologically verified tumors/No,  mice in group. 
J; Normal (SB)FI mice have an incidence of lymphoreticular tumors of less than 5% at 1 
yr of age. 
rounding connective tissue.  The liver and lungs were heavily infiltrated.  Kid- 
ney  involvement  was  common  and  consisted  of  tumor  cell  deposits  in  the 
glomeruli or under the renal capsule. The thymus was atrophic, weighing from 
2 to 10 mg, with no histological evidence of tumor. Mice with tumor bore no 
evidence  of  histological  lesions  which  have  been  associated  with  acute  or 
chronic  GVHRs (11,  12),  except for slight plasma cellular reaction in the loose 
connective tissue about the lymph nodes and other organs.  Skin, bowel lining, 
blood vessels, kidneys, and ureters appeared undamaged. 
All of the  (SB)F1 mice which had received frozen and thawed S spleen cells 
developed tumors by 40 days. These results were identical with those obtained 
in (SB)F1 mice injected with viable S spleen cells (Table I). A tumor was first 
evident in one mouse in this group 28 days after the initial injection of frozen 
and  thawed  spleen cells.  There was no weight loss in any of the mice in this 
group.  The  tumors were  identical,  in  their gross  and  microscopic pathology, 
with  those observed in  (SB)F1  mice receiving viable S  spleen cells.  During  a 
4-month observation period,  tumors did not develop in  (SB)F1 mice receiving 
S liver, (SB)F1 spleen cells, or in normal (SB)FI mice. 
Tumors from eight (SB)F~ mice which had been injected with viable S spleen 
cells (group a) were transplanted initially into syngeneic (SB)F~ mice. All were 
accepted.  These  tumors were  then used for two purposes:  (a)  preparation  of 
cell-free extracts  (see  below),  and  (b)  transplantation  into  syngeneic  (SB)F1 
mice, parental  strain  mice,  S  and  B,  mice containing  a  parental  component, 
(NZB  >(  S)F1,  and  into  an unrelated  strain,  NZB  (Table  II). During  a  6- 
month observation period,  tumor growth was observed only in  (SB)F~ and B 
mice, and in none  of the other groups;  this was uniformly true for all of the 
eight original tumors. In those groups in which tumor acceptance occurred, this 
was clearly evident by the 4th wk after transplantation. The clinically observ- 
able rate of tumor growth was also uniform among the mice in each group. 
Tumors from eight  (SB)F1  mice which  had  been injected  with  frozen  and 
thawed  S spleen cells (group b) were transplanted  in a manner similar to the 1536  VIRAL  INDUCTION  OF  MUltlNE  LYMPHOMAS 
tumors arising in (SB)F1 mice injected with viable S spleen cells (previous para- 
graph).  The results were  also  similar;  that  is,  the  tumors  were  accepted by 
(SB)F1 and B, but not by S, (NZB X  S)F1, or NZB hosts. 
Cell-free preparations,  derived from tumors originating in  (SB)F1  mice in- 
jected with viable S spleen cells, were injected into newborn B or (BA)F1 mice. 
Cell-free extracts of seven of eight tumors resulted in tumor growth in such B 
or  (BA)F1 hosts  (Table III). The latent period from the time of injection to 
clinical evidence of tumor varied from 33 to 49 days. The tumors involved lymph 
nodes, spleen, liver, lung, and kidney. The thymus was not involved except late 
in the disease by direct extension from the adjoining mediastinal nodes. Histo- 
logically the tumors were predominantly lymphosarcomas with occasional areas 
of reticulum cell sarcoma. Four of the seven tumors induced in newborn mice 
by means of cell-free preparations were transplanted as a viable tumor cell sus- 
pension into weanling mice. Two tumors arising in B mice grew after transplan- 
tation into syngeneic B hosts, confirming the histologic diagnosis of a malignant 
tumor. Two tumors (of a total of three) which had developed in (BA)F1 new- 
borns were successfully transplanted into (BA)F1, B, and (SB)F1 hosts. Growth 
in (BA)F1 mice confirmed the histological diagnosis of a malignant tumor and 
TABLE  I[ 
Transplantation Characto'istics of GVHR-Induced  Lymphomas of  (SB)F1 Mice 
Host strain*  Tumor acceptance.+ 
(SB)F1  8/8 
S  0/8 
B  s/8 
NZB  0/8 
* 6-8  weanling  mice  in  each  group. 
No.  tumors  accepted/No,  tumors transplanted;  6  months observation  period. 
TABLE  III 
Tumor lndl~ctlon by Cell-Free Preparations of GVHR-Induced Lymphomas 
Tumor No.  Newborn hosts  Tumor incidence  Latent period 
days 
1  B  10/10  49 
2  (BA)F1  6/6  47 
3  (BA)F1  5/5  47 
4  B,  (BA)F1  4/5,  4/4  42,  42 
5  B  3/3  44 
6  B  2/2  48 
7  (BA)I:'I  0/4  72* 
8  B  8/8  33 
* Observation period. EUGENE  A.  CORNELIUS  1537 
provided evidence of the viability of the tumor cell suspension; growth in B  and 
(SB)F1 hosts indicated that the tumors were B in phenotype. 
DISCUSSION 
Various theories have been proposed to explain the induction of lymphomas 
by the  GVHR  (1-5). These include the actual  injection of  malignant  donor 
cells, excessive imnmnological stimulation of the donor cells by the foreign com- 
ponent of the F1 hybrid host, proliferation of reticuloendothelial tissue in re- 
sponse  to  lymphoid  tissue  damage  associated  with  this  reaction,  mutagenic 
effects of lymphocyte breakdown products, immunologic suppression,  and re- 
lease or activation of an oncogenic virus. In the present experiments, evidence 
for a  viral  etiology of such  tumors is provided by the  characteristics of the 
strains of mice used for GVHR tumor induction, the very short latent period 
required for tumor induction,  the induction of tumors which differ markedly 
antigenically from either donor or host, and, most significantly, the induction of 
tumors in F~ mice with frozen and thawed extracts of donor spleens, as well as 
the induction of tumors in newborn hosts with cell-free preparations of GVHR- 
induced lymphomas. 
Intensive studies of the mouse strains used in these experiments, S and B, 
have shown conclusively that both strains carry tumorigenic virus; however, 
tumor  inducibility,  histology,  and  organ  distribution differ markedly. The  S 
strain exhibits an incidence of spontaneous reticulum cell sarcoma increasing with 
age,  reaching  90%  by  13  months  (13).  Histologically the  tumors  resemble 
Hodgkin's  disease  of humans.  Dmochowski  and  coworkers have proved  the 
viral  origin of such  tumors  (14,  15).  Vertical  transmission  of the virus from 
mother to embryo was also demonstrated. In contrast to S mice, the B strain 
exhibits a very low incidence of spontaneous lymphoma (16). In an extensive 
series of ingenious experiments, Kaplan and his associates established that the B 
strain is a carrier of a latent leukemogenic virus which is readily activated by 
X-irradiation (17). The induced tumor, a lymphatic leukemia, originated in the 
thymus with subsequent involvement of the lymphoid tissues. Gross, who first 
demonstrated  a  viral  etiology of spontaneous  murine  lymphomas  (18),  con- 
firmed  the  principle of  radiation  activation  of latent  leukemogenic virus  in 
another low-leukemia strain,  C3H  (19).  Recent  experiments in  the  author's 
laboratory have provided evidence that subline 1 of the B strain is also a carrier 
of a latent leukemogenic virus. 
Firstly, parabiosis of (BA)F1 hybrid mice with syngeneic partners, followed 
by supralethal irradiation of one partner and separation of the partners 1 month 
later, has resulted in a significantly increased incidence of lymphomas, compared 
with normal control mice, in the shielded, nonirradiated partner (unpublished 
observations).  Secondly,  it  has  been  noted  that  neonatally  thymectomized 
(BA)F1 hybrid mice develop a significantly higher incidence of spontaneously 
occurring lymphomas (as well as autoimmune changes) than do normal controls 1538  VIRAL  INDUCTION  OF  MURINE  LYMPHOMAS 
(20). Thirdly, when (SB)F1 mice were injected with massive doses of B spleen 
cells,  all  of the F1 recipients developed reticulum cell  sarcomas by 120 days. 
After transplantation,  these tumors were accepted by both the F1 and the B 
parent  (i.e.,  the donor strain parent) but not by the S parent,  and were pre- 
sumed to be of donor genotype (4). All of these findings can be explained best if 
it is assumed that subline 1 of the B  strain  (and its hybrids) is  a  carrier of a 
latent leukemogenic virus which can be released or activated by various dis- 
turbances of the cellular environment, such as after irradiation of a parabiotic 
partner, neonatal thymectomy, or the induction of a graft-versus-host  reaction. 
From these considerations, it appears that the (SB)F1 h)%rid mouse, the host 
animal in the present experiments, is a carrier of tumor-inducing virus(es) de- 
rived from both parents. However, the very fact that tumors were induced in 40 
days after injection of small numbers of S spleen cells into (SB)F1 mice but only 
after 120 days after massive doses of B cells may indicate that the part played 
by the virus of S mice is more important in terms of tumor inducibility in the 
GVHR involving (SB)F1 hybrid mice than that played by the virus of B mice. 
The latter virus may, on the other hand, be more important in the determina- 
tion of the histocompatibility characteristics of the induced tumors (see below). 
The latent period for tumor induction, 40 days after the initial injection of S 
parental  spleen cells into  (SB)F1  mice,  is  far shorter than  that  observed for 
GVHR induction of tumor utilizing other strain combinations (1-4, 6, 7). This, 
as well as the small number of cells required for tumor induction, is probably a 
reflection of the quantity of oncogenic virus in the spleen cell inoculum, and of 
an unusual degree of host susceptibility. (Comparative experiments in this lab- 
oratory, utilizing various murine strain cGmbinations, have amply demonstrated 
the apparent immunological vigor of S spleen cells in the GVHR, in terms of F1 
hybrid morbidity and mortality [21]. While this may be an exaggerated expres- 
sion of cellular immunity peculiar to this strain, it is quite possible that the virus 
of the S strain, released or activated as a result of the cell damage associated 
with the GVHR, may at least be partly responsible.) 
The induction of tumors in  (SB)F1 hybrid mice after injection  of viable S 
spleen cells, which after transplantation grew in syngeneic (SB)F1 and B mice, 
but not in S mice, the parental strain used for induction of the  GVHR, is an 
interesting problem in the relationship of viral oncogenesis and cell surface com- 
position. Antigenic changes in tumor cells may be considered in terms  of anti- 
genic loss or gain (22). Mitcheson (23) and Klein and Klein (24) have provided 
evidence of uniparental preference of heterozygous F1 lymphomas and sarcomas 
which  was  interpreted as  being caused bv loss  of antigens  derived from the 
other parent.  In the present experiments, all  tumors induced in F1 mice were 
uniformly accepted by only one parental strain. This contrasts with the vari- 
able results in the above studies, and implies a highly specific mechanism in the 
determination of their antigenic composition. Since B ~  (SB)Frinduced tumors 
were also accepted by B mice, a common mechanism in the determination of the EUGENE  A.  CORNELIUS  1539 
tumor cell surface composition may be operative in both GVHRs involving the 
same F1 hybrid. Cell culture studies have demonstrated that  the B  radiation 
leukemia virus could rescue a defective murine sarcoma virus genome; the re- 
sultant infectious virus particle carried the envelope of the B virus (25). Thus 
in GVHR-induced tumors in (SB)F1 mice, irrespective of the parental cell donor 
used for initiation of the reaction, the B virus may be acting as a helper to the S 
virus; the S virus is a more powerful oncogenic agent but the B virus is a more 
potent determinant of the tumor cell surface composition. The antigenic compo- 
sition of the tumor celt membrane would be altered from that of the normal cells 
of the (SB)F~ host to a sufficiently high concentration of B antigen, relative to 
S-derived antigen,  to be accepted immunologically by B  hosts. This suggests 
that the B  virus, when activated, is capable of controlling the genome of the 
(SB)F~ host cell or at least that portion derived from the B parent. At the pres- 
ent time, little is known about the exact relationship between murine leukemia 
virus particles and  the expression of virus-induced cell  surface antigens  (26). 
(In this regard, the F1 hybrid animal, containing tumor-inducing viruses from 
one or both parental strains, may be of particular value in the study of the re- 
lationship between oncogenic virus and tumor antigenicity. In pure strain mice, 
a virally induced tumor would arouse no particular interest if it were found to be 
acceptable to syngeneic pure strain hosts on transplantation; but the F1 mouse, 
which is unable to reject parental strain tissue, would permit the development 
of tumors with parental antigenicity, and more significantly, the detection of 
their unique character by subsequent transplantation studies.) 
Weanling (SB)FI mice injected with frozen and thawed spleen cells from S 
donors developed lymphomas with a latent period, distribution, and histology 
very similar to those after the injection of viable S spleen cells into similar hy- 
brids.  This  most  unexpected finding constitutes  strong  evidence for  a  viral 
etiology of GVHR-induced tumors. It indicates that the induction of tumors in 
this reaction does not depend specifically on an immunological mechanism but 
appears merely to depend on the liberation or activation of a sufficient quantity 
of oncogenic virus. The fact that tumors induced in  (SB)F1 mice with frozen 
and thawed S spleen cells were identical in their transplantation characteristics 
with those induced by viable S spleen cells supports this interpretation. This re- 
sult is also of significance from the point of view of tumorigenesis in general, in 
that a cell-free extract of normal mouse spleen carries oncogenic information. 
This provides corroborative evidence for the finding that viruses isolated from 
normal spleens of BALB/c mice produce leukemia when inoculated into new- 
born syngeneic mice (R. J. Peters et al., manuscript in preparation) [27]. Addi- 
tional support is thus provided for the Huebner-Todaro viral oncogene hypoth- 
esis, in that exogenously added viruses may transform cells by "switching on" 
the endogenous oncogenic machinery (the induced tumors were antigenically 
different from donor or host). Electron microscope studies of various organs of 
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the liver (14). The absence of tumor development in (SB)F1 mice injected with 
intact S liver cells may therefore be due to the low concentration of virus within 
the liver or to preservation of the liver cells with relative absence of free virus. 
Tumor induction  in  newborn mice  after injection  of  cell-free preparations 
from GVHR-induced tumors is also strong evidence for a viral etiology of such 
tumors. In contrast to most such studies, the latent period was extremely" short, 
as little as 33 days. This is probably due to a combination of several factors: (a) 
a high virus content in the tumor, as well as further concentration with poly- 
ethylene glycol; and (b) the use of (BA)F1 and B recipients. The latent virus of 
these newborn hosts may be acting as a helper virus to that contained in the 
inoculum. 
Transplantation of two of the three tumors induced in (BA)F1 newborn mice 
revealed that in both instances the tumors were antigenically B  tumors. Con- 
ceivably, viable cells were contained in the original cell-free preparation of the 
GVHR-induced tumors. The technique of preparation of the cell-free inoculum, 
however, was a standardized procedure. Also, cell-free extracts of spontaneous 
lymphomas of (BA)F1 mice have induced lymphomas in B hosts, whereas viable 
suspensions of such (BA)F1 tumors were not  accepted by B mice (unpublished 
observations). Far more attractive is the concept of a helper role for the latent 
virus of the (BA)F1 newborns, derived from the B parent, for the S virus of the 
cell-free extract, as in tumors induced in (SB)F1 mice by frozen and thawed S 
spleen cells: 
In his studies of the radiation induction of leukemia, Kaplan noted a para- 
doxical increase in leukenfia incidence when the same total dose of radiation was 
given not as a single exposure but in several fractions separated by a few days 
(28).  Maximal tumor incidence was achieved by using young adult  (age 30-36 
days)  mice irradiated  at 4- or 8-day intervals for a  total of four equal doses. 
Since the mutagenic action of radiation is characterized by independence of mu- 
tation yield with respect to dose rate and fractionation, somatic mutation was 
clearly an untenable mechanism for the leukemogenic action of radiation.  Pre- 
vious experiments in this laboratory revealed that a single injection of 40 X  106 
S spleen cells into weanling (SB)F~ mice resulted in a 17 % incidence of tumors in 
8  months  (21).  By contrast,  in the present experiments, when  a  similar total 
dosage of S spleen cells was divided into five equal doses given at weekly inter- 
vals, tumor incidence increased to 100% in only 40 days. It is therefore tempting 
to consider somatic mutation improbable as a cause of GVHR-induced tumors 
on these grounds alone.  Further  experiments by Kaplan, and by this  author, 
have demonstrated a viral etiology of radiation- and GVHR-induced tumors, re- 
spectively. A  detailed  study of the influence of host age and the number and 
spacing  of  the  parental  cell  injections  on  the  incidence  of  GVHR-induced 
lymphomas has not yet been carried out. In this regard, the present experiments 
already show a maximal tumor incidence when these parameters approximate 
those in the radiation experiments, and suggest a common underlying mecha- 
nism, using both modal:ties, in the temporal aspects of viral leukemogenesis. EUGENE  A.  CORNELIUS  1541: 
There is no literature on the relationship of the viruses of the S and B strains. 
of mice; however, the present experiments, as well as other investigations in this 
author's laboratory, provide some insight into their mutual oncogenic potential. 
Since (SA)F1 mice also have a low incidence of spontaneously occurring lym- 
phomas (personal observations) the infrequency of such tumors in (SB)F1 mice- 
as compared with that in the parental strain S cannot be attributed to a special 
strain-specific influence of the B component of the hybrid. In the GVHR modelL 
A ~  (BA)F1, tumors were induced only after many months, and were trans- 
plantable only to A and (BA)FI but not to B hosts (4). This contrasts with the 
present experiments in which S ~  (SB)F1 resulted in tumors which were pheno- 
typically B. Also,  the  S virus does not appear to possess vigorous oncogenic 
powers universally in S ~  F1 GVHRs; current experiments, in which S spleen. 
cells have been injected into (NZB X  S)F1 hybrids in weekly doses, already in- 
dicate that the remarkably rapid oncogenesis of the S --* (SB)FI combinatioI~ 
will not be duplicated. Thus, presently available data seem to indicate that the 
viruses of the  S  and B  (subline  1)  strains  of mice  are  strongly and perhaps 
uniquely synergistic in tumor induction. These strains and their hybrid would 
therefore appear to possess exciting possibilities for further studies of tumor in- 
duction by cooperating viruses utilizing immunological and other means. Such 
investigations are important for further elucidation of the oncogene theory of 
tumorigenesis (27). 
Control of tumor development can operate at various levels and is a complex 
and as yet poorly understood phenomenon (27). Tumor induction in any situa- 
tion, including the GVHR, will occur when the combined factors for expression 
exceed a  threshold. In the present experiments, it seems likely that high con- 
centrations of oncogenic virus in a susceptible host have readily overcome in- 
hibitory influences, resulting in  "acute" induction of tumors.  I  suggest  that 
tumor induction in more chonic GVHRs in mice is also basically viral in nature, 
with various factors facilitating the expression of viral oncogenic potential. Thus 
excessive immunological stimulation of donor cells might result in virus activa- 
tion or liberation. (Donor-type tumors have not yet been investigated for a viral 
etiology.) Impaired immunological reactivity has been demonstrated in F1 host 
mice during the GVHR (29, 30) and could permit the survival of clones of neo- 
plastic cells which might otherwise be eliminated. This, together with the well- 
known phenomenon of declining thymus function with age, may be important 
in tumor induction in chronic GVHRs involving a major portion of the life-span 
of the host animal (4). 
SUMMARY  AND  CONCLUSIONS 
When weanling (SJL/J X  C57BL/1)F1 hybrid mice were given five weekly 
injections of small doses of viable SJL/J spleen cells,  so as to induce a graft- 
versus-host reaction (GVHR), reticulum cell sarcomas were induced in all of the 
host mice by the 40th day after the first cell injection. Such tumors, on trans- 
plantation, were accepted by syngeneic (SJL/J X  C57BL/1)F1 and C57BL/1 1542  VIRAL  INDUCTION  OF  MURINE  LYMPtIOMAS 
hosts, but not by SJL/J or NZB mice. Cell-free extracts of SJL/J spleens in- 
jected into similar hybrids resulted in identical tumors in all hosts within  the 
same  period;  the  transplantation  characteristics  were  also  similar.  Normal 
(SJL/J  X  C57BL/1)F1 hybrids as well as similar hybrids injected with SJL/J 
liver or syngeneic F1 spleen cells did not develop tumors. 
Cell-free preparations of eight tumors induced in Fl'S by viable SLJ/J spleen 
cells were injected into newborn (C57BL/1  X  A)F1 and C57BL/1 mice: tumors 
were induced,  with seven of eight tumor preparations, with a  latent period of 
33-49 days. Such tumors were lymphosarcomas, and, in the case of (C57BL/1 X 
A)F1  hosts,  further  transplantation  revealed  that  they  were  antigenically 
C57BL/1  tumors. 
These experiments provide conclusive evidence for a viral etiology of GVHR- 
induced  tumors. Furthermore, tumor induction in the GVHR does not appear 
to depend specifically on an immunological mechanism but is most probably due 
to release or activation of a sufficient quantity of oncogenic virus within a cer- 
tain time period in a highly susceptible host. Comparison with radiation induc- 
tion of viral leukemia in mice revealed similarities in regard to optimal host age 
and the spacing of administration of the tumor-inducing agent. 
SJL/J mice carry a type C virus which causes a high incidence of spontaneous 
Hodgkin-like tumors by 1 yr of age; C57BL/1 mice do not develop lymphomas 
spontaneously but carry a latent leukemogenic virus. Their hybrid also has a 
low incidence of spontaneous lymphomas. Based on the results of these and pre- 
vious experiments, the viruses of these strains of mice appear to be highly syner- 
gistic in tumor induction in the GVHR. The SJL/J virus is a powerful oncogenic 
agent. The C57BL/1  virus may be a helper virus to the SJL/J, but is a more 
powerful determinant of the antigenic composition of the induced tumors. This 
suggests that the virus of C57BL/1 mice, when activated, is capable of control- 
ling the C57BL/1  genome. Because of the ease and rapidity of viral tumor in- 
duction,  the SJL/J and C57BL/1 strains of mice, with their Fa hybrid, should 
be useful  for further  study  of  the  mechanisms controlling  induction  of such 
tunlors. 
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